RC48-ADC Clinical Trials

1 actively recruiting trial

No change since May 2026

Also known as: Disitamab Vedotin

Pipeline

Phase 3: 1

Top Sponsors

RemeGen Co., Ltd.1

Indications

HER2-expressing1
Urothelial Carcinoma1
Cancer1

Other1 trial

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.